Mineralys Therapeutics vs Rein Therapeutics
MLYS and RNTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MLYS and RNTX compare
Mineralys Therapeutics is the larger company, worth 42 times as much as Rein Therapeutics ($1.3B against $30.7M).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MLYS | RNTX |
|---|---|---|
| Size and price | ||
| Market cap | $1.3B | $30.7M |
| Share price | $14.48 | $0.356 |
| Change, 1 year | −64.6% | −71.5% |
| Change, 5 years | – | −97.3% |
| Beta (5Y) | 2.45 | 2.30 |
| Employees | 76 | 10 |
| StockData Score | ||
| Total score | 6 | 6 |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 2.3× | 0.6× (better) |
| Profitability | ||
| Return on equity | −80.9% (better) | −96.4% |
| Return on invested capital | −93.8% (better) | −145% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 34.46 (better) | 4.27 |
| Altman Z-score | 4.35 (better) | −8.96 |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Buyback yield | – | −179% |
| Shareholder yield | 0.00% (better) | −179% |
| Ownership | ||
| Held by institutions | 114% | 47.3% |
| Held by insiders | 24.1% | 9.6% |
| Insider net buying, 12 months | −$19.2M | $74.7K (better) |
| Short interest, % of float | 11.5% | 0.91% |
Go deeper
- MLYS stock overview
- MLYS income statement
- MLYS valuation and score
- RNTX stock overview
- RNTX income statement
- RNTX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.